Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
与二肽基肽酶-4抑制剂相比，恩格列净与成人（无论是否患有心血管疾病）心血管风险降低相关：来自欧洲和亚洲的恩格列净疗效和安全性比较研究（EMPRISE）结果
期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/s12933-023-01963-9
Vistisen, Dorte; Carstensen, Bendix; Elisabetta, Patorno; Lanzinger, Stefanie; Tan, Elise Chia-Hui; Yabe, Daisuke; Kim, Dae Jung; Sheu, Wayne H-H; Melzer-Cohen, Cheli; Holl, Reinhard W; Núñez, Júlio; Ha, Kyoung Hwa; Halvorsen, Sigrun; Langslet, Gisle; Karasik, Avraham; Nyström, Thomas; Niskanen, Leo; Guleria, Sonia; Klement, Riho; Carrasco, Marc; Foersch, Johannes; Shay, Christina; Koeneman, Lisette; Hoti, Fabian; Farsani, Soulmaz Fazeli; Khunti, Kamlesh; Zaccardi, Francesco; Subramanian, Anuradhaa; Nirantharakumar, Krishnarajah
